
Skin cancer peaks in summer – so why is early detection still an afterthought?
As UV exposure intensifies, so does the risk of developing malignant skin lesions. Melanoma, the deadliest form of skin cancer, is directly linked to sunburns and overexposure to UV radiation. According to data from SkinVision, skin cancer cases, including melanoma are most commonly checked and detected during the summer months. One reason is that we're simply seeing more of our skin.
Short sleeves, swimsuits and sunbathing make skin more visible, both to ourselves and to others, making it a time when early signs are more likely to be noticed. And yet many people let that moment slip by without taking action.
We pack sunscreen. We stay in the shade. We wear hats. But we rarely check our skin, and that may be one of the most significant missed opportunities in cancer prevention.
Melanoma rates have risen by more than 30 per cent in the past decade in the UK, with forecasts predicting further increases by 2040. And while skin cancer is often associated with older adults, cases in young people, particularly women under 40, are climbing fast, largely driven by tanning culture, sporadic sunburns and limited awareness.
Skin cancer is one of the most preventable cancers – and one of the most detectable. The warning signs of melanoma are often visible: a mole that changes in shape, colour or size, or a new spot that doesn't look quite right.
When caught early, melanoma has a five-year survival rate of around 99 per cent. But that figure drops sharply – to around 75 per cent or lower – once the cancer has spread. Early diagnosis is not just beneficial, it's life-saving.
Yet too many people ignore skin changes until they become impossible to dismiss. And during summer, when changes may be easier to notice, distractions, travel and a sense of holiday relaxation mean that many warning signs go uninvestigated.
People delay appointments until they return from holiday. Or they tell themselves they'll deal with it in autumn. But that delay can be critical.
Summer's paradox: high risk, low action
There's an irony to how we treat summer. Our skin is exposed more than at any other time of year, but our healthcare routines are often paused.
Sunburn risk increases. UV radiation peaks. In some countries, people accumulate more sun exposure during two weeks abroad than in the rest of the year combined. And yet we often deprioritise health checks in favour of holiday plans.
What's more, UV damage is cumulative. Even if melanoma doesn't 'start' in summer, years of exposure build risk. A mole that's changed this summer may be a sign of damage done long ago, but it's still a signal that needs to be checked.
Why early detection still gets left behind
Part of the problem is logistical. Seeing a dermatologist during the summer is often harder than usual. Clinics are understaffed. Appointments are delayed. Many people are abroad or traveling. And without a pressing reason, it's easy to put off a check-up until autumn, or later.
But it's also cultural. We're conditioned to treat skin changes as cosmetic, not clinical. A new freckle? Probably harmless. A mole that looks different? Maybe it's always been that way.
Unlike breast or prostate cancer, there's no widespread cultural routine for skin checks. No regular screening reminders. No strong public narrative around vigilance.
This mindset delays care. And while many people are vigilant with sunblock, they forget to follow up on what's already there: a mark, a mole, a spot that's changed.
Technology can close the gap
This is where digital tools such as SkinVision come in.
Rather than waiting weeks for an appointment, users can analyse a suspicious mole or spot on their skin and receive feedback immediately. The app uses clinically validated AI to assess whether the mark is low risk or may require follow-up. Behind the algorithm, a team of dermatologists provides oversight where needed.
This doesn't replace doctors, but it does provide a valuable first step. Especially during summer, when travel, limited clinic access and wait times can all discourage action.
Importantly, most assessments result in reassurance, helping users avoid unnecessary worry or appointments. But in the small percentage of high-risk cases, that quick feedback leads to timely medical care.
Expanding the summer health conversation
We already talk about protecting skin in summer. But protection is just one half of the story. Detection completes the loop.
It's not about replacing advice, it's about enhancing it:
Keep wearing sunscreen
Keep staying in the shade
But also check your skin
And if something seems off, don't wait.
Making skin checks part of the summer health checklist, just like hydration or UV alerts, can shift behaviour in small but powerful ways.
Skin cancer doesn't develop overnight. It grows silently. But the signs are often right in front of us, and summer may be the only time we're looking.
Instead of missing that window, we should be seizing it.
Let this be the year that summer season becomes a moment for action, not just risk. A moment to combine sun protection with proactive skin checks. A moment to notice a mark, take a closer look and follow up, even while on holiday.
Because when it comes to skin cancer, early detection isn't just better. It's life-saving.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Independent
an hour ago
- The Independent
Study pinpoints ‘critical time windows' for illnesses that pose dementia risk
Developing illnesses such as heart disease and diabetes before the age of 55 could increase the chance of having dementia in later life, a new study suggests. Strokes or the onset of mental health conditions such as anxiety and depression between 55 and 70 could also increase risk two-fold, according to research. Experts at the University of Oxford said up to 80% of dementia patients suffer from two or more chronic health conditions, but there is a 'lack of understanding' when it comes to specific illnesses, age of onset and the link to dementia. They identified 'critical time windows' in which certain illnesses pose the greatest risk to patients. For the study, published in Brain Communications, researchers analysed data from 282,712 people using the UK Biobank and looked at patterns for 46 chronic health conditions. They found that heart conditions such as heart disease and atrial fibrillation, as well as diabetes, before the age of 55 was most strongly linked to dementia risk. However, from 55 to 70 years of age, mental health conditions such as anxiety and depression, as well as conditions such as stroke, increased the risk of dementia two-fold. Sana Suri, an associate professor and Oxford Brain Sciences senior fellow, said: 'Although we knew that multimorbidity increased the risk of dementia, it was unclear which combinations of health conditions had the most impact and in what sequence. 'This study has identified how specific illnesses tend to co-exist with each other, and also the critical time windows in which they could pose the greatest risk.' Elsewhere, the study suggests people who have conditions such as heart disease and diabetes in middle age, followed later by conditions such as stroke and mental health disorders were at the greatest risk of developing dementia. Ms Suri said the presence of other illnesses should be taken into account when estimating a person's risk of developing dementia, and could help develop strategies that aim to reduce risk at certain points in life. She added: 'This study identified associations between multimorbidity and dementia risk but we need to understand more about why this happens. 'We also need to try to replicate the study in more diverse groups of people to ensure the results are representative of the population. 'Future studies could examine whether efforts to manage or prevent cardiovascular problems in early-to-midlife, followed by mental health and neurological disorders when people are in their fifties and sixties, might reduce the risk of dementia.'


The Independent
an hour ago
- The Independent
Routine eye scan could predict 10-year heart attack and stroke risk
A scan which forms part of a routine eye test could help predict a person's risk of having a heart attack or stroke within the next 10 years, a study suggests. Researchers used artificial intelligence (AI) to analyse digital retinal photographs, which are taken to capture images from the back of the eye to look for certain conditions. The technology was able to produce personalised risk predictors in less than a second. It is hoped the simple test could one day be offered alongside blood pressure and cholesterol checks to allow doctors to treat patients earlier. For the study, published in the journal Cardiovascular Diabetology, researchers at the University of Dundee trialled the AI software on the eye scans of people with type 2 diabetes. Those with the condition have routine eye tests to check for diabetic retinopathy, a condition where high blood sugar levels damage the blood sugar in the retina. Dr Ify Mordi, British Heart Foundation research fellow at the University of Dundee and consultant cardiologist, said: 'It may be surprising, but the eyes are a window to the heart. 'If there is damage or narrowing of the blood vessels at the back of the eye, there is a good chance that will also be seen in the blood vessels further inside the body, supplying the heart, which could lead to a heart attack or stroke.' Experts instructed the technology to initially look for warning signs on the images, such as blood vessel narrowing or blockages. It was then permitted to look for any detail in the photographs, such as the size or arrangement of blood vessels, before being trained using 4,200 images. The AI tool was able to predict the people who would go on to have 'major cardiovascular events', like heart attacks or strokes, within a decade with 70% accuracy. Dr Mordi added: 'This is a one-stop scan which is routinely performed and takes less than a minute. 'It could be an important part of the package, alongside blood pressure and cholesterol checks, in identifying people who could benefit from medication or lifestyle changes.' Professor Bryan Williams, chief scientific and medical officer at the British Heart Foundation, said: 'The more accurately we can detect someone's risk of a heart attack or stroke, the better the opportunities to prevent these happening. 'Cutting-edge innovations, like the use of retinal scans alongside health checks, could play a role in improving risk prediction, which is important if we are to reach the British Heart Foundation's goal to prevent 125,000 heart attacks and strokes in the UK by 2035. 'However, more research is needed to show this prediction accuracy is robust, and to determine the feasibility of incorporating retinal scans into clinical practice.' Reacting to the study, Dr Clare Jonas, research lead at the Stroke Association, said: 'AI analyses of health data, gathered through screening technology such as this eye scan, have exciting potential for better early detection, especially for those with diabetes who have a greater chance of having a stroke. 'Advances like these could make it easier for people at risk of stroke to take the right steps to stop it from happening. 'Whilst there are still many practical questions to answer about whether, when and how AI could be used in clinical practice, we hope the Government's 10 Year Health Plan will take such technological advances into account to stop more strokes from devastating people's lives.'


Daily Mail
an hour ago
- Daily Mail
Major study shatters RFK Jr's wild claims about autism causes
A major 20-year study of over one million children found no association between aluminum in vaccines and conditions like autism and ADHD. Findings in the sweeping investigation provide a rebuttal to oft-debunked claims about the use of aluminum salts in vaccines, which bolster the body's immune response, and purported ties to asthma, autoimmune diseases, and autism. DANISH researchers looked at 50 potential health effects in children taking a vaccine containing aluminum salts, including 36 immune system disorders like diabetes and celiac disease, nine allergy-related conditions, such as asthma and eczema, and five neurodevelopmental disorders, including autism and ADHD. They found no increased risk of autism, ADHD, asthma, or autoimmune disorders from the small amounts of aluminum in vaccines. In fact, vaccinated children showed slightly lower rates of neurodevelopmental conditions – a seven percent lower autism risk and a 10 percent lower ADHD risk – with no connection to allergic or immune problems. Aluminum adjuvants are safely used in several common childhood vaccines, including those protecting against diphtheria-tetanus-pertussis (DTaP/Tdap), hepatitis A and B, Haemophilus influenzae type b (Hib), and pneumococcal disease. The aluminum in vaccines acts as a booster, strengthening the body's immune response to the vaccine. The salts create a temporary irritation at the injection site, which helps the immune system recognize and remember the germ, allowing it to build long-lasting protection. During a June 2024 appearance on Joe Rogan's popular podcast, Kennedy falsely labeled aluminum as 'extremely neurotoxic,' mirroring the debunked rhetoric of the anti-vaccine group Children's Health Defense, which ties aluminum adjuvants to autism, contradicting decades of rigorous studies confirming vaccine safety. Senior study author Dr Anders Hviid, an epidemiologist at the Statens Serum Institut in Denmark, said: 'By analyzing data from more than one million Danish children, we found absolutely no indication that the very small amount of aluminum used in the childhood vaccination program increases the risk of 50 different health outcomes during childhood.' 'This is the first study of this scale and with such comprehensive analyses, and it confirms the strong safety profile of the vaccines we've used for decades in Denmark.' Since 1997, Denmark has offered, though not required, aluminum-containing vaccines for diseases including diphtheria, tetanus, whooping cough, and polio. Babies receive three doses by the age of one, with a booster dose at age five. The study tracked aluminum exposure from these vaccines, which ranged from 0.125 mg to 1 mg per dose. Using national health records, the team compared aluminum exposure levels to any of the 50 examined diagnoses between the ages of two and five. They accounted for factors like birth weight, family income and maternal health. With data spanning 24 years and encompassing 1.2 million children, some of whom were followed until age eight, the research team utilized statistical models that controlled for real-world variables, including doctor visits and parental smoking. 'We should not be concerned about aluminum used as an adjuvant in childhood vaccines. I think that's the core message,' Dr Hviid told Stat. The results were published this week in the Annals of Internal Medicine. The latest study was in response to a 2022 CDC report that found a possible link between aluminum used as an adjuvant in vaccines and allergies and asthma in children. Experts at the time pointed out limitations in CDC's methodology. It couldn't distinguish between aluminum from vaccines and environmental sources, such as food or air pollution. They also highlighted puzzling inconsistencies, such as one subgroup of vaccinated children showing no increased risk of asthma despite higher exposure to aluminum. Children are exposed to aluminum in various ways, separate from childhood vaccines. In their first six months, babies get roughly four milligrams of aluminum from vaccines, a minuscule amount. A milligram is one-thousandth of a gram, and a gram is the weight of one-fifth of a teaspoon of water. At the same time, breastfed infants ingest about 10 milligrams, formula-fed babies 40 milligrams and those on soy formula 120 milligrams. Israeli immunologist Dr Yehuda Shoenfeld is the central figure in the debate over the safety of aluminum salts in vaccines through his proposed 2011 Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA) hypothesis. His published work suggests aluminum-based vaccine adjuvants may trigger autoimmune responses in genetically susceptible individuals, forming the theoretical foundation for many concerns about the safety of common childhood shots. However, while vaccine skeptics frequently cite Shoenfeld's papers and book on ASIA, the broader scientific community notes significant limitations. His hypothesis relies primarily on case reports and lacks consistent epidemiological support. Large-scale population studies have failed to validate any causal link between aluminum adjuvants and autoimmune conditions. The research comes as autism diagnoses have increased in the US to one in 31 children compared to one in 150 two decades ago. While Kennedy claims this could be blamed on environmental toxins like food additives and pesticides, autism experts believe the increase is due to better diagnostic criteria and more awareness.